ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » 2017 Pediatric Rheumatology Symposium

2:00PM-3:00PM
Abstract Number: 3
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study
2:00PM-3:00PM
Abstract Number: 4
Microbiota-Dependent Signals Regulate Inflammatory Myelopoiesis in a Murine Model of Macrophage Activation Syndrome
2:00PM-3:00PM
Abstract Number: 2
Murine Model of Arthritis Flare Identifies CD8+ Tissue Resident Memory T Cells in Recurrent Synovitis
2:00PM-3:00PM
Abstract Number: 1
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis
4:45PM-5:15PM
Abstract Number: 15
An Internet-based Self-management Program for Adolescents with Juvenile Idiopathic Arthritis – A Randomized Controlled Trial
4:45PM-5:15PM
Abstract Number: 17
Anti-endothelial cell antibodies in juvenile dermatomyositis
4:45PM-5:15PM
Abstract Number: 18
Bridging the gap between GWAS and mechanism in juvenile idiopathic arthritis using a novel high-throughput experimental screen
4:45PM-5:15PM
Abstract Number: 24
Development and Implementation of a “Data-In-Once” Model for a Pediatric Rheumatology Learning Health System
4:45PM-5:15PM
Abstract Number: 14
Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial
4:45PM-5:15PM
Abstract Number: 21
Enhancing Quality of Care in Childhood-Onset Systemic Lupus Erythematosus by Improving Performance on Quality Indicator Measures in Cardiovascular and Bone Health
4:45PM-5:15PM
Abstract Number: 20
Enthesitis-Related Arthritis: Non-Peripheral Pattern is Associated with an Expansion of Peripheral Th17 Populations
4:45PM-5:15PM
Abstract Number: 23
Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies
4:45PM-5:15PM
Abstract Number: 16
Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups
4:45PM-5:15PM
Abstract Number: 22
Patient perception of barriers to taking medication in Juvenile Idiopathic Arthritis
4:45PM-5:15PM
Abstract Number: 13
Prevalence of Celiac Antibodies and IgA deficiency in Juvenile Idiopathic Arthritis
4:45PM-5:15PM
Abstract Number: 25
Reliability of the Physician Global Assessment Scores for Determination of Disease Activity Status within the Pediatric Rheumatology Care and Outcomes Improvement Network
4:45PM-5:15PM
Abstract Number: 11
Safety of Adalimumab ± Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA): STRIVE Registry
4:45PM-5:15PM
Abstract Number: 19
The Lymphocyte Repertoire in Juvenile Dermatomyositis
4:45PM-5:15PM
Abstract Number: 12
Use of Ultrasound to Determine Remission Status in Children with Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 154
“Celebrate Ability”: Structured Art Workshop as a Therapeutic Coping Strategy for Patients with Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 136
14-3-3π(eta) Protein in Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 133
3-D Explant Method Facilitates the Study of Lymphocytes in Synovium and Reveals a Population of Resident Memory-Like T Cells in Rheumatoid Arthritis
5:30PM-7:00PM
Abstract Number: 53
A Prospective Study to Assess for Changes in Mood with Initiation of Anti-TNF therapy: A Pilot Study
5:30PM-7:00PM
Abstract Number: 155
A Single Center Review of Health Related Quality of Life in Children with Systemic Lupus Erythematosus Using the Pediatric Quality of Life Inventory Version 4.0 Generic Core Scale
5:30PM-7:00PM
Abstract Number: 89
Abatacept as Adjunct Therapy for the Calcinosis of Juvenile Dermatomyositis: A Single-Center Experience
5:30PM-7:00PM
Abstract Number: 123
Acupuncture for Pediatric Chronic Pain Relief: A Review
5:30PM-7:00PM
Abstract Number: 146
Age-Related Differences in Neuronal High Mobility Group Box-1 and Resolvin D1 Receptors in Collagen-Induced Arthritis
5:30PM-7:00PM
Abstract Number: 134
Akkermansia Muciniphila May Be Permissive to Arthritis in the K/BxN Mouse Model of Arthritis
5:30PM-7:00PM
Abstract Number: 58
Analysis and Implications of Non-Invasive Knee Acoustical Emissions in Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 115
Anti-Phospholipid Antibodies in Children with Down Syndrome
5:30PM-7:00PM
Abstract Number: 76
Applying 2016 MAS Criteria to Systemic onset Juvenile Idiopathic Arthritis Patients with Diagnosis of Macrophage Activation Syndrome
5:30PM-7:00PM
Abstract Number: 116
Arthritis as First Presenting Symptom of Inflammatory Bowel Disease: A Case Control Study
5:30PM-7:00PM
Abstract Number: 87
Assessment of Endothelial Dysfunction and Atherogenic Risk Factors in Children with Juvenile Dermatomyositis
5:30PM-7:00PM
Abstract Number: 106
Atypical manifestations and main misdiagnoses of Takayasu’s arteritis in childhood: a multicenter study of 71 patients
5:30PM-7:00PM
Abstract Number: 131
Balancing JAK/STAT-signaling with tofacitinib may foster anti-inflammatory functions of human monocytes
5:30PM-7:00PM
Abstract Number: 65
Barriers at School for Children with Juvenile Idiopathic Arthritis (JIA) –A Patient Reported Outcome
5:30PM-7:00PM
Abstract Number: 47
Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study
5:30PM-7:00PM
Abstract Number: 74
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
5:30PM-7:00PM
Abstract Number: 97
Bortezomib is Efficacious in the Treatment of Refractory Neuropsychiatric SLE with Psychosis
5:30PM-7:00PM
Abstract Number: 55
Celiac Disease in Children Diagnosed with Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 129
Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus
5:30PM-7:00PM
Abstract Number: 126
Challenges in Transitioning Adolescents with Rheumatologic Diseases to Adult Care – The Brazilian Experience
5:30PM-7:00PM
Abstract Number: 108
Characteristics and long-term outcome of children and adolescents with initial diagnosis of Behçet’s disease in a tertiary care center in Brazil
5:30PM-7:00PM
Abstract Number: 85
Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America
5:30PM-7:00PM
Abstract Number: 152
Characteristics of Patients With Juvenile Idiopathic Arthritis in a US Healthcare Claims Database
5:30PM-7:00PM
Abstract Number: 150
Childhood-onset Takayasu Arteritis Associated with Mutations in CBL
5:30PM-7:00PM
Abstract Number: 107
Children with Relapsing Polychondritis are likely to be seen in the emergency room prior to establishing the diagnosis
5:30PM-7:00PM
Abstract Number: 137
Chromatin Landscapes and Genetic Risk For Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 88
Clinical Features and Frequency of Biologic use in Patients with Juvenile Dermatomyositis-associated Calcinosis
5:30PM-7:00PM
Abstract Number: 114
Clinical Features and Treatment Outcomes in Down’s Arthropathy
5:30PM-7:00PM
Abstract Number: 109
Clinical features of pediatric Behçet’s disease patients in Japan
5:30PM-7:00PM
Abstract Number: 71
Consensus-based diagnostic approach to systemic juvenile idiopathic arthritis in Germany
5:30PM-7:00PM
Abstract Number: 98
Contraceptive use, Counseling given and the Occurrence of Venous Thrombus Embolism in Adolescent Systemic Lupus Erythematosus
5:30PM-7:00PM
Abstract Number: 96
Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index and Skindex-29 with Cutaneous Childhood Lupus Erythematous
5:30PM-7:00PM
Abstract Number: 93
Corticosteroid Regimen Use in the Pilot Study of Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis
5:30PM-7:00PM
Abstract Number: 149
Deficiency of Complement C4A or Low Copy Number of Total C4 Genes, HLA-DRB1*15 and HLA-DRB1*03 Are Strong Genetic Risk Factors for Pediatric SLE of European Descent
5:30PM-7:00PM
Abstract Number: 101
Defining Active Features of Juvenile Localized Scleroderma
5:30PM-7:00PM
Abstract Number: 127
Description of first 40 patients from a Rheumatologic Transition Clinic in Chile
5:30PM-7:00PM
Abstract Number: 95
Development of Cognitive Behavioral Therapy (CBT) for Childhood-onset Systemic Lupus Erythematosus (cSLE) Treatment
5:30PM-7:00PM
Abstract Number: 82
Disease Burden and Social Impact of Chronic Nonbacterial Osteomyelitis on Affected Children and Young Adults
5:30PM-7:00PM
Abstract Number: 102
Duration of High-Dose Aspirin Therapy Does Not Affect Coronary Artery Outcomes in Kawasaki Disease
5:30PM-7:00PM
Abstract Number: 139
Dysregulation of miRNA in mononuclear cells of patients with enthesitis related arthritis
5:30PM-7:00PM
Abstract Number: 77
Effectiveness of Childhood Vaccinations in CAPS Patients Treated With Canakinumab: Results From an Open-Label Phase III Extension Study
5:30PM-7:00PM
Abstract Number: 94
Effects of Age and Gender on Reference Levels of Biomarkers Comprising the Pediatric Renal Activity Index for Lupus Nephritis (p-RAIL)
5:30PM-7:00PM
Abstract Number: 111
Eosinophilic Fasciitis in Children: Clinical Course and Response to Treatment from Two Large Academic Centers
5:30PM-7:00PM
Abstract Number: 147
Epigenetic and Transcriptomic Profiling of Primary Juvenile Idiopathic Arthritis Patient Cells: Better Understanding of Disease Pathogenesis
5:30PM-7:00PM
Abstract Number: 135
Epigenetic Profiling Of Juvenile Idiopathic Arthritis (JIA) Synovial Fluid Monocytes Points Towards a Role For Monocytes In Bone Damage
5:30PM-7:00PM
Abstract Number: 119
Establishment of registry for pediatric rheumatic diseases in Japan: Pediatric Rheumatology International Collaboration Unit Registry (PRICURE) survey
5:30PM-7:00PM
Abstract Number: 64
Evaluating Levels of Activity and Health-Related Quality of Life in a Pilot Cohort of Youth Athletes with Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 42
Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age With Systemic Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 113
Exploring the role of pediatric rheumatologists in the diagnosis and management of autoimmune encephalitis
5:30PM-7:00PM
Abstract Number: 141
Expression of Siglec-10 on Synovial Fluid CD14dim Monocytes Was Decreased in Juvenile Idiopathic Arthritis Patients
5:30PM-7:00PM
Abstract Number: 73
Factors Associated with Etoposide Usage in Children with Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 66
Feasibility Testing of An Internet-Based Psycho-Educational Game for Children with Juvenile Idiopathic Arthritis and Their Parents
5:30PM-7:00PM
Abstract Number: 75
Ferritin:ESR, A Predictor of MAS?
5:30PM-7:00PM
Abstract Number: 83
Feverprints: A Crowdsourcing Study of Temperature in Health and Disease
5:30PM-7:00PM
Abstract Number: 68
HLA-DRB1 in Non-Hispanic African American Children with Juvenile Idiopathic Arthritis and Chronic Anterior Uveitis
5:30PM-7:00PM
Abstract Number: 125
How Do Health Literacy, Numeric Competencies and Patient Activation Impact Transition Readiness in Adolescents and Young Adults with Rheumatologic Diseases?
5:30PM-7:00PM
Abstract Number: 52
How Young People with Juvenile Idiopathic Arthritis and Their Caregivers Weigh the Risks of the Disease and its Treatment: A Mixed-Methods Study
5:30PM-7:00PM
Abstract Number: 41
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 70
Impact of Systemic Juvenile Idiopathic Arthritis/Still’s Disease on Adolescents as Evidenced Through Social Media Posting
5:30PM-7:00PM
Abstract Number: 100
Improvement of Salivary Gland Ultrasound Findings in Juvenile Sjögren’s Syndrome after Systemic Corticosteroid Treatment
5:30PM-7:00PM
Abstract Number: 143
Influence of Age and Sex on Collagen-Induced Arthritis
5:30PM-7:00PM
Abstract Number: 132
Influence of Juvenile Idiopathic Arthritis Fibroblast-like Synoviocytes and Mature Chondrocytes on Each Other in Culture: A Pilot Study
5:30PM-7:00PM
Abstract Number: 105
Isolated Pediatric Pulmonary Capillaritis: A Comprehensive Single-Center Review of Disease Course, Management, and Prognosis
5:30PM-7:00PM
Abstract Number: 145
JAK Inhibition Rescues Novel PSMB8 Mutations
5:30PM-7:00PM
Abstract Number: 144
Linear Discriminant Analysis of Cultured Fibroblast-like Synoviocytes Identifies 6 Candidate Genes Which Predict Extended Course in Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 46
Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis
5:30PM-7:00PM
Abstract Number: 44
Long-term Efficacy and Safety of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results From a Phase III Extension Study
5:30PM-7:00PM
Abstract Number: 48
Methotrexate use and route of administration in JIA: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry
5:30PM-7:00PM
Abstract Number: 138
Modeling Transcriptional Rewiring in Neutrophils through the Course of Treated Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 140
Modular Gene Expression Discrimination of Juvenile Idiopathic Arthritis and Inflammatory Bowel Disease Subphenotypes in Peripheral Blood
5:30PM-7:00PM
Abstract Number: 92
Mycophenolate Mofetil is an Effective Induction Therapy Agent in Childhood-onset Pure Membranous Lupus Nephritis
5:30PM-7:00PM
Abstract Number: 142
Neutrophils and monocytes in the early inflammatory cascade of systemic onset Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 62
Novel Approach to Quantifying Joint Pathology Via Musculoskeletal Ultrasound in Newly Diagnosed Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 148
Oral Microbial Profile in Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 118
Oxygen Saturation Recordings in Pediatric Rheumatology Patients At Risk For Lung Disease
5:30PM-7:00PM
Abstract Number: 60
Paediatric Arthritis Rehabilitation Exercise Study
5:30PM-7:00PM
Abstract Number: 49
Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 63
Performance of Disease Activity Measures in Pediatric Patients With Enthesitis-related Arthritis
5:30PM-7:00PM
Abstract Number: 91
Peri-pubertal Onset of Systemic Lupus Erythematosus is Associated with Shorter than Expected Adult Height
5:30PM-7:00PM
Abstract Number: 99
PILOT STUDY MEASURING HEPCIDIN AND ARTERIAL STIFFNESS IN CHILDREN WITH SLE AND LUPUS NEPHRITIS
5:30PM-7:00PM
Abstract Number: 79
Predicting Colchicine Response in Patients with Undefined Autoinflammatory Diseases
5:30PM-7:00PM
Abstract Number: 84
Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
5:30PM-7:00PM
Abstract Number: 78
Predictors of Outcome Following Tonsillectomy in Periodic Fever, Aphthous Stomatitis Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome
5:30PM-7:00PM
Abstract Number: 159
Preferences and Satisfaction in a Pediatric Multi-specialty Infusion Center
5:30PM-7:00PM
Abstract Number: 81
Preliminary Consensus Treatment Plans for Periodic Fever, Aphthous Stomatitis, Pharyngitis and Adenitis: The Foundation for Capturing Treatment Responses in PFAPA from the CARRA PFAPA Subcommittee
5:30PM-7:00PM
Abstract Number: 122
Presenting Manifestations of Amplified Musculoskeletal Pain Syndrome in Males versus Females
5:30PM-7:00PM
Abstract Number: 56
Prevalence of Serum 14-3-3η in Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 158
Quality of Referral Letters to Pediatric Rheumatology and Its Impact on Access to Care
5:30PM-7:00PM
Abstract Number: 57
Quantification of Dynamic MRI examinations in Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 67
Relapse and Remission in Children with Chronic Non-Infectious Uveitis Treated with Methotrexate and Tumor Necrosis Factor-α Inhibitors
5:30PM-7:00PM
Abstract Number: 110
Risk Factors for Poor Health-Related Quality of Life in Children with Inflammatory Brain Diseases
5:30PM-7:00PM
Abstract Number: 90
Risk of Serious Infections in Juvenile Dermatomyositis patients treated with biological response modifiers including rituximab and abatacept
5:30PM-7:00PM
Abstract Number: 104
Rituximab Treatment for Chronic Steroid-Dependent Henoch-Schonlein Purpura
5:30PM-7:00PM
Abstract Number: 45
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
5:30PM-7:00PM
Abstract Number: 121
Safety Of Biological Response Modifiers In Childhood Autoimmune Rheumatic Diseases From A Single North Indian Centre
5:30PM-7:00PM
Abstract Number: 151
Severe Phenotype of Mevalonate-kinase Deficiency in the Czech Republic
5:30PM-7:00PM
Abstract Number: 59
Six Minute Walk Test in Children with Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 160
Stepping Stones to Transition Smartly
5:30PM-7:00PM
Abstract Number: 72
Systemic Juvenile Idiopathic Arthritis in a Colombian cohort: onset and clinical course
5:30PM-7:00PM
Abstract Number: 156
Teaching High Value Musculoskeletal Care Through Online Simulation Cases
5:30PM-7:00PM
Abstract Number: 69
The Disease Burden of Systemic Juvenile Idiopathic Arthritis for Patients and Caregivers: An International Health Related Quality of Life Survey and Retrospective Chart Review
5:30PM-7:00PM
Abstract Number: 117
The Effect of Bisphosphonate Use on Bone Density Measurements in Patients with Muscular Dystrophy
5:30PM-7:00PM
Abstract Number: 86
The myositis-specific autoantibody and myositis-associated autoantibody phenotypes in Japanese juvenile idiopathic inflammatory myopathies
5:30PM-7:00PM
Abstract Number: 103
The Performance of a New Risk Assessment Scoring System in Detecting IVIG Resistance in Kawasaki Disease as Compared to the Kobayashi and Egami Scores in a Large Single Centre Canadian Cohort
5:30PM-7:00PM
Abstract Number: 51
The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA
5:30PM-7:00PM
Abstract Number: 43
Tocilizumab Use in Pediatrics With Systemic Juvenile Idiopathic Arthritis: Single Center Data
5:30PM-7:00PM
Abstract Number: 153
Training pediatric rheumatology fellows intra-articular injection techniques and skills using a cadaver based musculoskeletal curriculum
5:30PM-7:00PM
Abstract Number: 54
Treatment and 1-year outcomes of an inception cohort of Australian children with JIA
5:30PM-7:00PM
Abstract Number: 80
Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades
5:30PM-7:00PM
Abstract Number: 128
Treatment Response in Polyarticular Juvenile Idiopathic Arthritis is Associated With Transcriptional Changes and Chromatin Reorganization in CD4+ T cells
5:30PM-7:00PM
Abstract Number: 50
Tumor necrosis factor-α (TNFα) inhibitor-induced psoriasis in juvenile idiopathic arthritis (JIA) patients
5:30PM-7:00PM
Abstract Number: 124
Underutilization of Social Workers for Mental Health Care of Adolescents in Pediatric Rheumatology: A Mixed Methods Study
5:30PM-7:00PM
Abstract Number: 112
Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder
5:30PM-7:00PM
Abstract Number: 120
Use Of Thalidomide From A Tertiary Level Pediatric Rheumatology Centre In India
5:30PM-7:00PM
Abstract Number: 157
Utility of Mailed Reminders for Uveitis Screening Guidelines in Patients with Juvenile Idiopathic Arthritis
5:30PM-7:00PM
Abstract Number: 130
Validation of MRP8/14 serum levels as biomarker for the diagnosis of systemic juvenile idiopathic arthritis in fever of unknown origin
5:30PM-7:00PM
Abstract Number: 61
Which Juvenile Idiopathic Arthritis patient is more likely to have Temporomandibular Joint involvement?
2:00PM-3:00PM
Abstract Number: 7
Activation of Immature, Transitional B cells by Integrated BCR, TLR and TACI signals promotes systemic autoimmunity in high BAFF settings
2:00PM-3:00PM
Abstract Number: 5
Effects of Puberty on Systemic Lupus Erythematosus:  Results of a multi-center prospective longitudinal observational study in children entering puberty with SLE
2:00PM-3:00PM
Abstract Number: 8
Examination of Reported Risk Loci from Candidate Gene Studies of Systemic Juvenile Idiopathic Arthritis Identifies Link between IL1RN Variation and both Disease Susceptibility and Response to Interleukin-1 Directed Therapy
2:00PM-3:00PM
Abstract Number: 6
High Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth
2:30PM-3:00PM
Abstract Number: 9
Biologically-Based Approach for Classifying Chronic Childhood Arthritis
2:30PM-3:00PM
Abstract Number: 10
Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88
5:15PM-5:45PM
Abstract Number: 33
An extracellular ionic milieu renders human granulocytic S100A12 into a pro-inflammatory TLR4-binding alarmin
5:15PM-5:45PM
Abstract Number: 27
Assessing the Safety of Kidney Biopsies Performed on Childhood-onset Systemic Lupus Erythmatosus Patients
5:15PM-5:45PM
Abstract Number: 30
Cross-sectional Analysis of Depression and Medication Non-Adherence in Childhood-onset Systemic Lupus Erythematosus
5:15PM-5:45PM
Abstract Number: 28
Dyslipidemia in Juvenile Dermatomyositis
5:15PM-5:45PM
Abstract Number: 26
Gray Matter Volume Loss in Youth with SLE
5:15PM-5:45PM
Abstract Number: 32
High Mobility Group Box 1 Protein in Children with Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis
5:15PM-5:45PM
Abstract Number: 37
Increased Involvement of Teenagers with Juvenile Idiopathic Arthritis in Treatment Decisions Using Medication Choice Cards: Preliminary Report from a Case-Control Study
5:15PM-5:45PM
Abstract Number: 38
Knowledge Translation in Juvenile Idiopathic Arthritis Research in Canada: A Focus on Pediatric Rheumatologists and Allied Health Professionals
5:15PM-5:45PM
Abstract Number: 35
Kv1.3 Expression on Urinary Leukocytes in Lupus Nephritis:  Potential for Targeted Immunotherapy
5:15PM-5:45PM
Abstract Number: 40
Perspectives of young people with Juvenile Idiopathic Arthritis, their caregivers, and health care providers on transition to adult care: Informing development of a transition toolkit
5:15PM-5:45PM
Abstract Number: 31
Predicting therapy response to IL-1 blockade in systemic JIA: a biomarker search
5:15PM-5:45PM
Abstract Number: 39
Rheumapalooza:  A rheumatology curriculum in evolution
5:15PM-5:45PM
Abstract Number: 29
Spinal Cord Inflammation in Children with Small Vessel Primary CNS Vasculitis
5:15PM-5:45PM
Abstract Number: 36
The Association of Obesity with Pediatric Psoriatic Arthritis
5:15PM-5:45PM
Abstract Number: 34
The SLCO1B1 *14 Allele is Associated with Poor Response to Subcutaneous Methotrexate in Patients with Juvenile Idiopathic Arthritis

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology